Tolerance and intolerance to factor VIII: A clinical perspective

  • Ernest Briët
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)


In this chapter I will discuss four aspects of inhibitor formation in patients with hemophilia A: why most patients with hemophilia are and remain tolerant to factor VIII (F.VIII), why some patients who are primarily tolerant to F.VIII get inhibitors later, how many patients get inhibitors, and how we can (re-)induce tolerance in patients with inhibitors.


Factor VIII Immune Tolerance Recombinant Factor VIII Severe Hemophilia Inhibitor Development 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    van Rood JJ, Claas FHJ. The influence of allogeneic cells on the human T and B cell repertoire. Science 1990; 248: 1388–1393.PubMedCrossRefGoogle Scholar
  2. 2.
    McMillan CW, Shapiro SS, Whitehurst D, et al. The natural history of factor VIILC inhibitors in patients with hemophilia A: A national comparative study. II. Observations on the initial development of factor VIILC inhibitors. Blood 1988; 71: 344–348.PubMedGoogle Scholar
  3. 3.
    Peerlinck K, Arnout J, Gilles JG, Saint-Remy J-M, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115–118.PubMedGoogle Scholar
  4. 4.
    Rosendaal FR, Nieuwenhuis HK, Van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 2180–2186.PubMedGoogle Scholar
  5. 5.
    Briët E, Rosendaal FR, Kreuz W, et al. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products (letter to the editor). Thromb Haemost 1994; (submitted).Google Scholar
  6. 6.
    Lusher JM, Salzman PM, Monoclate study group. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Semin Hematol 1990; 27 (Suppl 2): 1–7.PubMedGoogle Scholar
  7. 7.
    Addiego JE, Jr., Gomperts E, Liu S-L, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIC immune-affinity chromatography. Thromb Haemost 1992; 67: 19–27.PubMedGoogle Scholar
  8. 8.
    Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and the Kogenate Previously Untreated Patient Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A-Safety, efficacy, and development of inhibitors. N Engl J Med 1993; 328: 453–459.CrossRefGoogle Scholar
  9. 9.
    Bray GL, Courter SG, Lynes M, Lee M, Gomperts E, and the Recombinate Study Group. Safety, efficacy and inhibitor risk of recombinant factor VIII (Recombinate) in a cohort of previously untreated patients (PUP’s) with severe hemophilia (abstract). Thromb Haemost 1993; 69: 1205.Google Scholar
  10. 10.
    . Guerois C, Rothschild C, Laurian Y, et al. Incidence of inhibitors specific for factors VIII (FVIII) or factor IX (FIX) in severe hemophiliacs A and B only treated with very high purity FVIII or FIX SD concentrates (abstract). Thromb Haemost 1993; 69: 852.Google Scholar
  11. 11.
    Lusher JM, Arkin S, Abildgaard CF, et al. Inhibitor development in previously untreated patients (PUPS) with hemophilia receiving Kogenate: 4.5 year follow-up data, including response to immune tolerance (IT) with Kogenate (abstract). Blood 1993; 82, Suppl 1: 153.Google Scholar
  12. 12.
    Rizza CR, Matthews JM. Effect of frequent factor VIII replacement on the level of factor VIII antibodies in Haemophiliacs. Br J Haematol 1982; 52: 13–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Brackmann HH, Gormsen J. Massive factor VIII infusion in haemophiliac with factor VIII inhibitor, high responder (letter to the editor). Lancet 1977; 2: 933.PubMedCrossRefGoogle Scholar
  14. 14.
    Brackmann HH, Egli H. Treatment of haemophilia patients with inhibitors. In: Seligsohn U, Rimon A, Horoszowski H, eds. Haemophilia. London: Castle House, 1981: 113–120.Google Scholar
  15. 15.
    Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181–195.PubMedGoogle Scholar
  16. 16.
    Nilsson IM, Sundqvist SB, Freiburghaus C. Extra-corporeal protein A sepharose and specific affinity chromatography for removal of antibodies. Prog Clin Biol Res 1984; 150: 225–241.PubMedGoogle Scholar
  17. 17.
    Nilsson IM, Bemtorp E, Zetterval O. Induction of split tolerance and clinical cure in high responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986; 83:9169:9173.Google Scholar
  18. 18.
    Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988; 318: 947–950.PubMedCrossRefGoogle Scholar
  19. 19.
    Nilsson IM, Berntorp E, Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 1993; 70: 56–59.PubMedGoogle Scholar
  20. 20.
    van Leeuwen EF, Mauser-Bunschoten EP, van Dijken PJ, Kok AJ, Sjamsoedin- Visser EJM, Sixma JJ. Disappearance of factor VIILC antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986; 64: 291–297.PubMedCrossRefGoogle Scholar
  21. 21.
    Mauser-Bunschoten EP, Nilsson IM, Kasper CK. Immune tolerance: A 1990 approach. In: Lusher JM, Kessler CM, eds. Hemophilia and von Willebrand’s disease in the 1990’s. Amsterdam: Excerpta Medica, 1991: 265–269.Google Scholar
  22. 22.
    White GC, Taylor RE, Blatt PM, Roberts HR. Treatment of high titre anti-factor VIII antibody by continuous factor VIII administration. Report of a case. Blood 1983; 62: 141–145.PubMedGoogle Scholar
  23. 23.
    Stenbjerg S, Ingerslev J, Zachariae E. Factor VIII inhibitor treatment with high doses of factor VIIL Thromb Res 1984; 34: 533–537.Google Scholar
  24. 24.
    Gomperts ED, Jordan S, Church JA, Sakai R, Lernire J. Induction of tolerance to factor VIII in a child with a high titre inhibitor: In vitro and in vivo observations. J Pediatr 1984; 104: 70–75.PubMedCrossRefGoogle Scholar
  25. 25.
    Aznar JA, Jorquera JI, Peiro A, Garcia I. The importance of corticosteroids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in hemophilia A. Thromb Haemost 1984; 51: 217–221.PubMedGoogle Scholar
  26. 26.
    Wensley RT, Burn AM, Redding OM. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors using low doses of factor VIII (abstract). Thromb Haemost 1985; 54: 227.Google Scholar
  27. 27.
    Wensley RT, Burns AM, Reading OM. Induction of tolerance to factor VIII in haemophilia A with inhibitor using low dose of human factor VIII (abstract). Rie Clin Lab 1986; 16: 104.Google Scholar
  28. 28.
    Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB. The Danish Study Group. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: A description of eleven patients treated. Thromb Haemost 1987; 58: 1049–1052.Google Scholar
  29. 29.
    Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65–85.PubMedCrossRefGoogle Scholar
  30. 30.
    Mariani G, Solinas S, Pasqualetti D, et al. Induction of immunotolerance in hemo¬philia for high titre inhibitor eradication: A long term follow-up. Thromb Haemost 1989; 62: 835–839.PubMedGoogle Scholar
  31. 31.
    Gruppo RA. Immune tolerance induction with once weekly factor VIII infusions in patients with hemophilia A and inhibitors (abstract). Thromb Haemost 1991; 65 (Suppl): 1168.Google Scholar
  32. 32.
    Nilsson IM, Berntorp E. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX. Prog Clin Biol Res 1990; 324: 69–78.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Ernest Briët
    • 1
  1. 1.Hemostasis and Thrombosis Center, Department of HematologyUniversity HospitalLeidenThe Netherlands

Personalised recommendations